White Paper
Beyond The Label: Turning Neurovascular Clinical Practice into Portfolio Strategy
How MedTech leaders can turn emerging clinical signals into smarter strategic decisions
Nov 17, 2026

Neurovascular clinical practice can evolve faster than Medical Devices labeling, evidence pathways and reimbursement. For MedTech manufacturers, recurring off-label use may therefore be more than an isolated clinical workaround. In the right circumstances, it can signal unmet need, evidence gaps, access barriers, device-fit limitations or potential lifecycle opportunities.

In this new white paper, Beyond The Label: Turning Neurovascular Clinical Practice into Portfolio Strategy, IQVIA MedTech explores how manufacturers can distinguish isolated clinical activity from recurring signals that warrant further investigation, while maintaining appropriate claims and scientific-exchange boundaries.

What Medical Devices manufacturers can learn

Download the white paper to explore how your teams can:

  • Detect emerging signals across literature, claims, registries, field insights, expert centers and KOL feedback.
  • Assess clinical and commercial relevance, including clinical rationale, patient need, payer friction, competitive activity and market potential.
  • Strengthen governance with appropriate claims controls, surveillance and scientific-exchange boundaries.
  • Define evidence requirements, from registries and real-world evidence to PMCF, health-economic evidence and prospective studies.
  • Choose the right strategic pathway, whether that means monitoring, further study, device refinement, access strategy, indication expansion, partnership, investment or stopping.

The objective is not to turn every emerging use into an investment opportunity. It is to give MedTech teams a disciplined way to determine which signals are credible, repeatable and strategically relevant.

Click the Contact us button to find out how IQVIA MedTech can support your evidence, access and portfolio strategy.

FAQs

Recurring off-label use can provide an early signal of unmet clinical need, evidence gaps, reimbursement friction, device-fit limitations or potential lifecycle opportunities. Manufacturers should evaluate whether the pattern is recurring, clinically coherent and strategically material before determining whether further evidence or investment is warranted.
IQVIA MedTech proposes a five-stage framework: Detect, Assess, Govern, Generate Evidence and Choose Pathway. This enables teams to evaluate clinical rationale, frequency, outcomes, patient need, reimbursement considerations, competition and market potential before determining an appropriate response.
Relevant evidence can include registries, real-world evidence, publications, surveillance data, claims patterns, structured customer feedback, health-economic evidence, prospective studies and clinical trials. The appropriate evidence strategy depends on the nature and maturity of the signal and the decision it needs to support.
Clinical permissibility does not automatically translate into reimbursement or market access. Coding, payment, site capabilities, referral pathways and payer evidence requirements can materially affect the attractiveness and timing of an opportunity.
IQVIA MedTech combines therapeutic expertise, real-world data, claims and access analytics, clinician and KOL insights, competitive intelligence and strategic consulting to help manufacturers identify signals, assess opportunities and determine appropriate evidence, governance and investment strategies.

Related solutions